At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 37 enrolled
Drug / intervention
PF-04691502drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Dose-Escalation Study To Evaluate Safety, Pharmacokinetics, And Pharmacodynamics Of The PI3K/MTOR Inhibitor PF-04691502 In Adult Patients With Advanced Malignant Solid Tumors
In Brief
A Phase 1 clinical trial evaluating PF-04691502 for Cancer. Completed, enrolled 37 participants across 7 sites.
Detailed Summary
A phase 1 dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of PF-04691502 in adult cancer patients with solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartDec 2009
Primary CompletionMar 2011
Study CompletionApr 2012
TodayJul 2026
First PostedJun 25, 2009
Enrollment StartDec 1, 2009
Primary CompletionMar 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.0 years ago
Interventions
PF-04691502drug
Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.